



Correction to: Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection

Mathieu Paul Rodero¹ · Stéphane Pelleau² · Anne Welfringer-Morin³ · FJDM study group · Darragh Duffy⁴ · Isabelle Melki^{5,6,7} · Brigitte Bader-Meunier^{8,7}

Published online: 7 October 2021

© Springer Science+Business Media, LLC, part of Springer Nature 2021

Correction to: Journal of Clinical Immunology

<https://doi.org/10.1007/s10875-021-01119-y>

Due to typesetting mistake, the institutional authors (FJDM Study group) were not properly presented.

The original version has been corrected.

FJDM Study group Vincent Bondet⁴

Cyril Gitiaux^{9,10}

Julie Bonigen³

Antoine Fayand¹

Laurence Courdavault Vagh Weinmann¹¹

Emmanuel Mahe¹²

Jean Luc Charuel¹³

Marie-Alexandra Alyanakian¹⁴

Jean Philippe Herbeuval¹

Michael White²

¹ Chimie & Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Université Paris Descartes, CNRS, UMR8601 Paris, France

² Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France

³ Department of Dermatology, Université de Paris AP-HP-5, Necker-Enfants Malades Hospital, Paris, France

⁴ Translational Immunology Lab, Institut, Pasteur, Paris, France

⁹ Reference Centre for Neuromuscular Diseases, Necker-Enfants Malades Hospital, AP-HP, Paris, France

¹⁰ Department of Paediatric Neurophysiology, Necker-Enfants Malades Hospital, AP-HP, Paris University, Paris, France

¹¹ CH Argenteuil, Virology, Argenteuil, France

¹² Department of Dermatology, Hospital of Argenteuil, Argenteuil, France

¹³ Laboratory of Immunology, La Pitié Hospital, AP-HP, Paris, France

¹⁴ Service d'Immunologie Biologique, Hôpital Necker-Enfants Malades, Assistance Publique- Hôpitaux de Paris (AP-HP), Université de Paris, Paris, France

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s10875-021-01119-y>.

✉ Brigitte Bader-Meunier
brigitte.bader-meunier@aphp.fr

¹ Chimie & Biologie, Modélisation et Immunologie pour la Thérapie (CBMIT), Université Paris Descartes, CNRS, UMR8601 Paris, France

² Infectious Diseases Epidemiology and Analytics Unit, Department of Global Health, Institut Pasteur, Paris, France

³ Department of Dermatology, Université de Paris AP-HP-5, Necker-Enfants Malades Hospital, Paris, France

⁴ Translational Immunology Lab, Institut, Pasteur, Paris, France

⁵ Laboratory of Neurogenetics and Neuroinflammation, Imagine, Institute, Paris University, Paris, France

⁶ General Paediatrics, Department of Infectious Disease and Internal, Medicine, Reference Centre for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Robert Debré, HospitalParis, AP-HP, France

⁷ Department of Paediatric Hematology-Immunology and Rheumatology, Necker-Enfants Malades Hospital, AP-HP, Paris, France, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Paris, France

⁸ Laboratory of Immunogenetics of Paediatric Autoimmunity, Imagine Institute, Inserm U 1163, Paris University, Paris, France